Related Experiment Video
Updated: Aug 15, 2026
07:39
Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
Subependymal giant cell tumors in tuberous sclerosis complex
Suzanne Goh1, William Butler, Elizabeth A Thiele
1Massachusetts General Hospital, Department of Neurology, Boston, MA 02114-3117, USA.
Neurology
|October 27, 2004
Summary
Subependymal giant cell tumors (SGCT) in tuberous sclerosis complex (TSC) patients may require reclassification. Early diagnosis and monitoring are crucial, especially for those with symptoms or potential for obstruction, with annual MRI screening recommended.
Area of Science:
- Neuro-oncology
- Genetics
- Neurology
Background:
- Subependymal giant cell tumors (SGCT) are associated with tuberous sclerosis complex (TSC).
- Current classification of SGCT as astrocytomas may be inaccurate.
- Understanding SGCT in TSC is critical for patient management.
Purpose of the Study:
- To describe clinical, radiologic, and outcome data for SGCT in TSC patients.
- To redefine and reclassify SGCT based on comprehensive criteria.
- To establish guidelines for diagnosis and monitoring of SGCT in TSC.
Main Methods:
- Retrospective review of 11 TSC patients with pathologically confirmed SGCT.
- Analysis of clinical presentations, radiologic findings, and postoperative outcomes.
- Follow-up duration ranged from 2 months to 36 years.
Main Results:
- Eight percent of TSC patients evaluated had SGCT.
- Patients presented with diverse symptoms or were asymptomatic.
- Poor outcomes were observed in patients aged 11 years or older at resection.
Conclusions:
- SGCT in TSC patients are likely of mixed glioneuronal lineage, suggesting current classification needs revision.
- Clinical diagnosis of SGCT requires specific symptoms or radiologic findings.
- Annual MRI screening is recommended for TSC patients until age 21; SGCT diagnosis warrants closer monitoring or intervention.
